human clinical trials

1st February 2008, Sydney, Australia: Medical Therapies Limited (ASX: MTY),
today announced that it has completed recruitment for ‘first in human’
clinical trials of CuprindoTM to determine its safety, tolerability and systemic
absorption characteristics.

“This is the most exciting development we’ve had to date and comes after six
months of thorough stability and pre-clinical trials on CuprindoTM,” said CEO
Maria Halasz.

Dosing of the first group of healthy volunteers is expected during the week of
4th February 2008.

The trial participants will apply CuprindoTM suppositories twice daily and they
will report in patient diaries on any adverse events. Full physiological and
biochemical analysis will also be completed at base line, day 3 and day 8 of
the trial. Results of the trial are expected to be available in April 2008.